RYTM Q1 2023 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+665.6% YoY

Gross Profit

$10M87.6% margin

Operating Income

-$53M-458.0% margin

Net Income

-$52M-455.0% margin

EPS (Diluted)

$-0.91

QoQ Revenue Growth

+30.5%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$36M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$346M

Total Liabilities

$126M

Stockholders' Equity

$220M

Cash & Equivalents

$110M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$1M	+665.6%
Gross Profit	$10M	$1M	+692.4%
Operating Income	-$53M	-$53M	+0.3%
Net Income	-$52M	-$53M	+1.1%